2020-01-08T10:10:01-06:00 2019-06-30 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 100172703 990 2018-07-01 131837442 CANCER RESEARCH INSTITUTE % ALFRED MASSIDAS CANC 2126887515 29 BROADWAY 4TH FLOOR NEW YORK NY 10006 JILL O'DONNELL-TORMEY CEO 2126887515 2020-01-08 true CANDICE METH P01306891 2129498700 64.238.150.4 26505220200085000000 2020-01-08 P AA55D71A41C1CFB2889B26AEF7762F6090100DB9 AA55D71A41C1CFB2889B26AEF7762F6090100DB9 2018 2020-09-23 17:36:50Z JILL O'DONNELL-TORMEY CEO 29 BROADWAY 4TH FLOOR NEW YORK NY 10006 48328207 false X www.cancerresearch.org X 1953 NY THE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVLEOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER. 37 37 35 385 0 0 23657555 40376590 0 0 1525018 1455927 26898 163175 25209471 41995692 21638503 25520160 0 0 3847248 4535893 0 0 2737455 4330426 4692337 29816177 34748390 -4606706 7247302 111819063 127608094 59626657 68809751 52192406 58798343 X THE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY TRANSLATIONAL, AND CLINICAL RESEARCH EFFORTS AIMED AT LEARNING HOW TO HARNESS THE POWER OF THE IMMUNE SYSTEM TO DIAGNOSE, TREAT, AND CURE CANCER. CRI ALSO COORDINATES SCIENTIFIC, MEDICAL, AND PATIENT EDUCATION CONFERENCES ON THE SUBJECTS OF IMMUNOLOGY AND IMMUNOTHERAPY, AND DISSEMINATES INFORMATION ABOUT ADVANCES IN TUMOR IMMUNOTHERAPY TO THE MEDIA, PUBLIC, AND MEDICAL AND SCIENTIFIC COMMUNITIES. false false 10371973 10371973 THE CRI ANNA-MARIA KELLEN CLINICAL ACCELERATOR PROGRAM IS AN ACTIVELY MANAGED VENTURE PHILANTHROPHY PROGRAM DESIGNED TO SPEED THE DEVELOPMENT OF CANCER IMMUNOTHERAPIES. THE STRATEGY FACILITATES RESEARCH COLLABORATION ACROSS LEADING BIOPHARMA COMPANIES AND AMONG 90 OF THE WORLD'S TOP CANCER RESEARCHERS. THE PROGRAM AIMS TO IDENTIFY AND KICK-START DEVELOPMENT OF NEXT GENERATION COMBINATION TREATMENTS USING THE MOST PROMISING DRUGS FROM DISPARATE COMPANIES. EACH PHILANTHROPIC INVESTMENT BRINGS A NEW CANCER TREATMENT TO PATIENTS, EMPOWERS ACADEMIC RESEARCHERS TO WORK MORE CLOSELY WITH INDUSTRY, AND CREATES THE POTENTIAL FOR SIGNIFICANT FUTURE RETURNS ON INVESTMENT BACK TO CRI TO MAKE THE VENTURE FUND SELF-SUSTAINING. 6250000 6250000 THE LLOYD J. STAR PROGRAM, LAUNCHED IN 2019, PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONG-TERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT, BUT RATHER AIMS TO PROVIDE A DEGREE OF FLEXIBILITY AND FREEDOM FOR INVESTIGATORS TO EXPLORE OUT-OF-THE-BOX AND DISRUPTIVE AVENUES OF RESEARCH. CANDIDATES SELECTED FOR THIS AWARD ARE EXPECTED TO BE FUTURE "STARS" IN THE FIELD OF CANCER IMMUNOLOGY: SCIENTISTS TAKING RISKS. 4769750 4769750 THE CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM PROVIDES SUPPORT TO FUND AND TRAIN YOUNG IMMUNOLOGISTS AND CANCER IMMUNOLOGISTS AT TOP UNIVERSITIES AND RESEARCH CENTERS AROUND THE WORLD. FELLOWS RECEIVE UP TO $175,500 OVER THREE YEARS TO COVER THE COST OF STIPEND OR SALARY, INSURANCE, AND OTHER RESEARCH-RELATED EXPENSES, SUCH AS TRAVEL TO CONFERENCES AND MEETINGS. OF THE MORE THAN 1,400 CRI POSTDOCTORAL FELLOWS FUNDED TO DATE, MANY HAVE SINCE BECOME HEADS OF MAJOR MEDICAL RESEARCH INSTITUTES, ACADEMIC LEADERS IN PRESTIGIOUS UNIVERSITIES, AND ADMIRED MENTORS TO THE NEXT GENERATION OF IMMUNOLOGISTS AND TUMOR IMMUNOLOGISTS. 8831145 4128437 30222868 true true false false false false false false false true true true false false true true true false false false true true false false true false false true false true false false false false false false false false true false false false false true false false false true X 19 0 true 35 true false false false false false true true false false false false false false X 37 37 false false false false false false false true true false false true true true true true true true true true true AL AK AZ AR CA CO CT DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X ALFRED MASSIDAS 2126887515 29 BROADWAY 4TH FL NEW YORK NY 10006 PAUL C SHIVERICK CO-CHAIRMAN 4.0 0.0 X X 0 0 0 ANDREW K TSAI CO-CHAIRMAN 4.0 0.0 X X 0 0 0 JOHN B FITZGIBBONS VICE CHAIRMAN 2.0 0.0 X X 0 0 0 EDGAR R BERNER VICE CHAIRMAN 3.0 0.0 X X 0 0 0 DONALD J GOGEL VICE CHAIRMAN 3.0 0.0 X X 0 0 0 JACQUES C NORDEMAN VICE CHAIRMAN 1.0 0.0 X X 0 0 0 ANDREW M PAUL VICE CHAIRMAN 2.0 0.0 X X 0 0 0 GEOFFREY O COLEY TREASURER 2.0 0.0 X X 0 0 0 THOMAS G MENDELL SECRETARY 1.0 0.0 X X 0 0 0 YACOV ARNOPOLIN TRUSTEE 2.0 0.0 X 0 0 0 PETER L BLOOM TRUSTEE 1.0 0.0 X 0 0 0 JENNIFER L BRORSEN TRUSTEE 0.5 0.0 X 0 0 0 JAMES M CITRIN TRUSTEE 0.5 0.0 X 0 0 0 W ROBERT DAHL TRUSTEE 1.5 0.0 X 0 0 0 GLENN J DESIMONE TRUSTEE 1.5 0.0 X 0 0 0 JOHN E ECKERSON TRUSTEE 0.5 0.0 X 0 0 0 SEAN P FAHEY TRUSTEE 1.0 0.0 X 0 0 0 MARGOT E FREEDMAN TRUSTEE 0.5 0.0 X 0 0 0 OLIVER R GRACE JR TRUSTEE 1.5 0.0 X 0 0 0 SANDRA COUDERT GRAHAM TRUSTEE 0.5 0.0 X 0 0 0 MICHAEL M KELLEN TRUSTEE 2.0 0.0 X 0 0 0 ALEXANDER P LYNCH TRUSTEE 0.5 0.0 X 0 0 0 BRIAN RIANO TRUSTEE 0.5 0.0 X 0 0 0 LIEF D ROSENBLATT TRUSTEE 0.5 0.0 X 0 0 0 FRANK V SICA TRUSTEE 0.5 0.0 X 0 0 0 JAMES A STERN TRUSTEE 1.0 0.0 X 0 0 0 MICHAEL B TARGOFF TRUSTEE 1.0 0.0 X 0 0 0 DIANE TUFT TRUSTEE 1.0 0.0 X 0 0 0 HEIDI UEBERROTH TRUSTEE 0.5 0.0 X 0 0 0 LAUREN VERONIS TRUSTEE 2.0 0.0 X 0 0 0 RONALD G WEINER Trustee 1.0 0.0 X 0 0 0 JIM WEISS Trustee 2.0 0.0 X 0 0 0 ANTONIO C Alvarez II Trustee 0.5 0.0 X 0 0 0 kamini Banga Trustee 2.0 0.0 X 0 0 0 Michael J Petrick trustee 0.5 0.0 X 0 0 0 Robert S Stolar Trustee 0.75 0.0 X 0 0 0 Peter Zhou Trustee 1.0 0.0 X 0 0 0 MAURICE J CUNNIFFE TRUSTEE (THRU 7/12/2018) 0.5 0.0 X 0 0 0 JILL O'DONNELL-TORMEY PHD CEO/DIR. OF SCIENTIFIC AFFAIRS 54.0 0.0 X 456388 0 53190 ALFRED R MASSIDAS CFO/DIR. OF HUMAN RESOURCES 45.0 0.0 X 293128 0 64473 LYNNE A RAPINO DIR.GRANT ADMIN/SPECIAL EVENTS 40.0 0.0 X 247837 0 62073 SHARON S SLADE DIR. OF STRATEGIC INIATIVES 40.0 0.0 X 207969 0 43225 VANESSA LUCEY DIRECTOR OF CVF & ACCELERATOR 40.0 0.0 X 186482 0 55973 BRIAN M BREWER DIR. OF MKTG & COMMUNICATIONS 40.0 0.0 X 172827 0 43440 RUPINDER KAUR SR. MANAGER OPS. & GIVING 40.0 0.0 X 131377 0 50448 QING HUA ZHANG CONTROLLER 40.0 0.0 X 111802 0 37190 JUN TANG SR MGR CRI VENT FUND&CLIN ACC 40.0 0.0 X 117814 0 37252 DEANNE T MARBACH DEVELOPMENT OFFICER 40.0 0.0 X 115504 0 21197 MARLA A LAWSON ASSOC DIR CORP & FDN RELATIONS 40.0 0.0 X 103115 0 35472 2144243 0 503933 11 false true false TWIST MARKETING 100 CAMPUS DRIVE SUITE 300 FLORHAM PARK NJ 07932 MARKETING 458370 IO COLLABORATIONS 7434 ARROWOOD ROAD BETHESDA MD 20817 STRATEGIC CONSULTING 334936 PARTNERS CAPITAL INVESTMENT GROUP L 1330 6TH AVE 22ND FLOOR NEW YORK NY 10019 INVESTMENT MANAGER 316291 THE GLOBAL EVENT TEAM LLC 28 W CENTRAL BLVD SUITE 200 ORLANDO FL 32801 EVENT PLANNING 258710 EMERGINGMED 2605 MERIDIAN PARKWAY SUITE 115 DURHAM NC 27713 PATIENT MANAGEMENT 170506 5 515069 2261152 37600369 139340 40376590 0 420877 420877 0 0 150243 130046 20197 0 20197 20197 6981283 5946233 1035050 1035050 1035050 256236 2261152 256236 0 0 0 0 0 0 EARLY GRANT TERMINATION REFUNDS 541990 96050 96050 MISCELLANEOUS 900099 46928 46928 142978 41995692 142978 1476124 24504890 24504890 0 1015270 1015270 0 780376 219394 279750 281232 0 2633042 1132871 477070 1023101 279665 107420 63991 108254 637958 254163 141155 242640 204852 80087 47323 77442 0 65916 36751 29165 91791 91791 0 0 316293 316293 756375 706690 49685 711479 291056 449 419974 0 0 0 432870 182211 99560 151099 331747 257248 10960 63539 0 1153300 1153300 0 0 39540 15380 9094 15066 37974 37974 SUPPLIES 215908 69682 30177 116049 TELEPHONE 43215 14405 14405 14405 POSTAGE AND SHIPPING 90715 16340 10505 63870 EQUIPMENT RENTAL & MAINTENANCE 74135 37407 11268 25460 331079 128303 67452 135324 34748390 30222868 1788067 2737455 X 16791829 2762434 4583383 24666709 34732857 41808127 289677 287139 0 0 0 0 0 0 0 0 414264 484257 577630 388734 211061 188896 14132717 14090530 40663275 43320002 0 0 0 0 0 0 111819063 127608094 667571 773477 58909145 68004733 0 0 0 0 0 0 0 0 0 0 0 0 49941 31541 59626657 68809751 X 31994656 34368286 16667691 20895328 3530059 3534729 52192406 58798343 111819063 127608094 X 7247302 1521683 -2163048 X false true X true false X 27002808 41576046 22009614 23657555 40376590 154622613 0 0 27002808 41576046 22009614 23657555 40376590 154622613 52029091 102593522 867994 767057 284686 321264 441074 2682075 -26103 -26103 128454 198695 91215 40026 142978 601368 157879953 0.64982 0.57031 X FORM 990, SCHEDULE A, PART II, SECTION B, LINE 10 OTHER INCOME: OTHER INCOME FOR THE CANCER RESEARCH INSTITUTE CONSISTS OF EARLY GRANT TERMINATION REFUNDS TO THE INSTITUTE FROM GRANTEES TOTALING $142,978, $40,026, $91,215, $198,695, AND $128,454 FOR THE FISCAL-YEARS ENDED JUNE 30, 2019, 2018, 2017, 2016, AND 2015, RESPECTIVELY. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7939697 33734 377937 150426 8200942 7487170 27900 668731 244104 7939697 6966728 23300 890431 393289 7487170 7224604 19840 -277716 6966728 6606693 34275 693636 110000 7224604 0.54000 0.43100 0.02900 false false 91569 15508 76061 486061 373226 112835 188896 PRIVATE EQUITY FUNDS 13003593 F HEDGE FUNDS 13669335 F FUND-OF-FUNDS 16647074 F 43320002 0 REFUNDABLE DEPOSIT 31541 31541 X 43685881 1521683 484799 2006482 41679399 316293 316293 41995692 37079944 484799 2163048 2647847 34432097 316293 316293 34748390 SCHEDULE D PART V LINE 4 THE INSTITUTE'S ENDOWMENT CONSISTS OF FOUR DONOR-RESTRICTED FUNDS AND A BOARD DESIGNATED FUND ESTABLISHED TO SUPPORT FELLOWSHIPS AND OTHER RESEARCH PROGRAMS. SCHEDULE D PART X LINE 2 THE INSTITUTE IS SUBJECT TO THE PROVISIONS OF THE financial accounting standards board's ASC TOPIC 740, INCOME TAXES, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. BECAUSE OF THE INSTITUTE'S GENERAL TAX-EXEMPT STATUS, MANAGEMENT BELIEVES ASC TOPIC 740 HAS NOT HAD AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON THE INSTITUTE'S FINANCIAL STATEMENTS. SCHEDULE D PART XII LINE 2D LOSS ON UNCOLLECTIBLE AMOUNTS OF $2,163,048, INCLUDED IN EXPENSES PER AUDITED FINANCIAL STATEMENTS, BUT NOT INCLUDED IN EXPENSES PER THE RETURN. true Central America and the Caribbean 0 0 Investments 37058539 Europe (Including Iceland and Greenland) 0 0 Grantmaking 400000 Middle East and North Africa 0 0 Grantmaking 240000 East Asia and the Pacific 0 0 Grantmaking 199770 North America 0 0 Grantmaking 175500 0 0 0 0 38073809 38073809 Europe (Including Iceland and Greenland) RESEARCH 200000 CHECK Middle East and North Africa RESEARCH 80000 CHECK Middle East and North Africa RESEARCH 80000 CHECK Middle East and North Africa RESEARCH 80000 CHECK Europe (Including Iceland and Greenland) RESEARCH 200000 CHECK North America RESEARCH 175500 CHECK East Asia and the Pacific RESEARCH 199770 CHECK 7 true false false false false false Monitoring Grants - PART I, QUESTION 2 Cancer Research Institute Inc. requires grant recipients to comply with stated terms and conditions governing each program, including the submission of annual progress reports and, where applicable institution- generated financial reports. Disbursement of funds is contingent upon acceptance of these terms and timely submission of reports. ACCOUNTING METHOD - PART I, QUESTION 3, COLUMN (F) AMOUNTS REPORTED ON THE ACCRUAL BASIS. FOREIGN GRANTS - PART II THE INSTITUTE'S FOREIGN GRANTS REPORTED IN SCHEDULE F, PART II, DO NOT INCLUDE AMOUNTS CONSIDERED TO BE PRESENT VALUE DISCOUNTS FOR CERTAIN GRANTS THAT EXTEND PAST ONE YEAR, WHICH HAVE BEEN REPORTED AS A REDUCTION OF GRANTS AND OTHER ASSISTANCE ON FORM 990, PART IX. Through the kit 1307821 1183811 124010 124010 Awards Dinner 896795 764569 132226 132226 6 312772 312772 2517388 2261152 256236 256236 256236 true Regents of the University of Michigan 2800 Plymouth road NCRC B10-A190 Ann Arbor MI 48109 386006309 501(C)(3) 400000 Research State University of New York BUFFALO 12 CAPEN HALL Buffalo NY 142601660 161331699 SUNY BUFFALO 200000 Research Columbia University Medical Center 701 W 168th Street New York NY 10032 135598093 501(C)(3) 400000 Research CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 E California Blvd Pasadena CA 91125 951643307 501(C)(3) 175500 Research The Rockefeller University 1230 York Avenue New York NY 10065 131624158 501(C)(3) 175500 Research Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MD 021394307 042103594 501(C)(3) 175500 Research Stanford University 291 Campus Drive Stanford CA 94305 941156365 501(C)(3) 551000 Research University of California San Francisco 513 Parnassus Avenue Med Sci San Francisco CA 94122 946036493 501(C)(3) 2127500 Research University of California Los Angeles Box 951405 2147 Murphy Hall Los Angeles CA 900951405 956006143 501(C)(3) 1250000 Research Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 131624182 501(C)(3) 2327500 Research Weill Medical College of Cornell university 1300 York Avenue New York NY 10065 131623978 501(C)(3) 1250000 Research Oregon Health & Science University 3181 SW Sam Jackson Park Rd CR1 Portland OR 972013098 931176109 501(C)(3) 1425500 Research Case Western Reserve University Ireland Cancer CTR 11100 Euclid Avenue Wearn 151 Cleveland OH 441065065 341018992 501(C)(3) 200000 Research Dana-Farber Cancer Institute Yawkey Center Suite 1220 450 Brookline Avenue Boston MA 02115 042263040 501(C)(3) 954167 Research Albert Einstein College of Medicine 1300 Morris Park Avenue Belfer Building Ste 312 Bronx NY 10461 472209056 501(C)(3) 200000 Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place New York NY 10029 136171197 501(C)(3) 200000 Research American Association for Cancer Research 615 Chestnut Street 16th Floor Philadelphia PA 19106 236251648 501(C)(3) 100000 Research University of Virginia Health System PO Box 800712 Charlottesville VA 22908 546001796 501(C)(3) 200000 Research Children's Hospital of Philadelphia 3401 Civic Center Blvd Philadelphia PA 19104 231352166 501(C)(3) 375500 Research Yale University School of Medicine PO Box 208055 333 Cedar Street New Haven CT 065208055 060646973 501(C)(3) 375500 Research University of California San Diego 9500 Gilman Drive La Jolla CA 92093 956006144 501(C)(3) 175500 Research University of Washington MEDICAL CENTER 1959 NE Pacific Street Seattle WA 98195 916001537 501(C)(3) 175500 Research Massachusetts General Hospital 55 Fruit Street Boston MA 02114 041564655 501(C)(3) 175500 Research Washington University School of Medicine 660 S Euclid Avenue St Louis MO 63110 430653611 501(C)(3) 175500 Research Johns Hopkins University School of Medicine 401 N Broadway Baltimore MD 21231 520595110 501(C)(3) 115000 Research Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 042774441 501(C)(3) 351000 Research University of Texas Southwestern Medical Center 5323 Harry Hines Blvd DALLAS TX 753909002 756002868 501(C)(3) 175500 Research Parker Institute for Cancer Immunotherapy One Letterman Drive Suite D3500 San Francisco CA 94129 473355381 501(C)(3) 16419724 RESEARCH THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 100010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501(C)(3) 175500 RESEARCH NATIONAL INSTITUTE OF ALLERGY&INFECTIOUS DISEASES 4 CENTER DRIVE BLDG 31 RM 7A-03 BETHESDA MD 208920460 520858115 NAT'L INSTITUTE 175500 RESEARCH UNIVERSITY OF PENNSYLVANIA DIVISION OF HEMATOLOGY 3400 CIVIC CENTER BLVD 10TH FLOOR OFFICE 10-306 PHILADELPHIA PA 19104 231352685 501(C)3 175500 RESEARCH 31 GRANT MONITORING - SCHEDULE I PART I, QUESTION 2 CANCER RESEARCH INSTITUTE INC. REQUIRES GRANT RECIPIENTS TO COMPLY WITH STATED TERMS AND CONDITIONS GOVERNING EACH PROGRAM, INCLUDING THE SUBMISSION OF ANNUAL PROGRESS REPORTS AND, WHERE APPLICABLE, INSTITUTION-GENERATED FINANCIAL REPORTS. DISBURSEMENT OF FUNDS IS CONTINGENT UPON ACCEPTANCE OF THESE TERMS AND TIMELY SUBMISSION OF REPORTS. DOMESTIC GRANTS - PART II THE INSTITUTE'S DOMESTIC GRANTS REPORTED IN SCHEDULE I, PART II, DO NOT INCLUDE AMOUNTS CONSIDERED TO BE PRESENT VALUE DISCOUNTS FOR CERTAIN GRANTS THAT EXTEND PAST ONE YEAR, WHICH HAVE BEEN REPORTED AS A REDUCTION OF GRANTS AND OTHER ASSISTANCE ON FORM 990, PART IX. X X X false false false false false false false false false JILL O'DONNELL-TORMEY PHD CEO/DIR. OF SCIENTIFIC AFFAIRS 456388 0 0 0 0 0 27500 0 25690 0 509578 0 0 0 ALFRED R MASSIDAS CFO/DIR. OF HUMAN RESOURCES 293128 0 0 0 0 0 27500 0 36973 0 357601 0 0 0 LYNNE A RAPINO DIR.GRANT ADMIN/SPECIAL EVENTS 247837 0 0 0 0 0 25100 0 36973 0 309910 0 0 0 SHARON S SLADE DIR. OF STRATEGIC INIATIVES 207969 0 0 0 0 0 21000 0 22225 0 251194 0 0 0 VANESSA LUCEY DIRECTOR OF CVF & ACCELERATOR 186482 0 0 0 0 0 19000 0 36973 0 242455 0 0 0 BRIAN M BREWER DIR. OF MKTG & COMMUNICATIONS 172827 0 0 0 0 0 17750 0 25690 0 216267 0 0 0 RUPINDER KAUR SR. MANAGER OPS. & GIVING 131377 0 0 0 0 0 13475 0 36973 0 181825 0 0 0 JUN TANG SR MGR CRI VENT FUND&CLIN ACC 117814 0 0 0 0 0 11562 0 25690 0 155066 0 X 31 139340 FMV false true true SCHEDULE M - NON-CASH CONTRIBUTIONS CRI USES A THIRD PARTY SERVICE ORGANIZATION TO RECEIVE DONATED VEHICLES, APPRAISE THE ITEMS AND PROMPTLY SELL THEM. FOR SERVICES RENDERED THE SERVICE ORGANIZATION RETAINS 30% OF THE NET PROCEEDS. PART III - STATEMENT OF PROGRAM ACCOMPLISHMENTS, LINE 4D CLINIC AND LABORATORY INTEGRATION PROGRAM: THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS QUALIFIED SCIENTISTS WHO ARE WORKING TO EXPLORE CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. THE PROGRAM FUNDS BASIC, PRECLINICAL, AND TRANSLATIONAL RESEARCH THAT CAN BE APPLIED DIRECTLY TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS PROVIDE UP TO $200,000 OVER TWO YEARS. TECHNOLOGY IMPACT AWARD: THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 12-24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES. IMPACT GRANTS: CRI'S IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED. PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 11 THE CEO AND THE CFO WORK WITH THE AUDIT FIRM TO PREPARE THE TAX RETURNS. A DRAFT COPY IS CIRCULATED TO THE ENTIRE BOARD FOR REVIEW AND COMMENTS, AFTER WHICH IT IS SIGNED AND FILED WITH RELEVANT AUTHORITIES. PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 12C ALL MEMBERS OF THE BOARD AND THE ENTIRE STAFF ARE GIVEN THE CONFLICT OF INTEREST DOCUMENT. THEY ARE ASKED TO ANSWER ALL QUESTIONS AND MAKE THE NECESSARY DECLARATIONS AND THEN SIGN THE DOCUMENT ON AN ANNUAL BASIS. PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 15 THE PROCESS FOR DETERMINING COMPENSATION OF THE CEO IS DETERMINED BY USING COMPARABLE DATA AND IS REVIEWED BY THE BOARD OF TRUSTEES CO-CHAIRMEN. PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 19 AT LEAST THE THREE MOST RECENT YEARS OF FINANCIAL INFORMATION ARE POSTED ON CRI'S WEBSITE. THE GENERAL PUBLIC CAN ALSO REQUEST A COPY TO BE SENT TO THEM, AS WELL AS VIEW THEM AT OUR OFFICES AT 29 BROADWAY, 4TH FLOOR NEW YORK, NY 10006. Governing documents are only distributed internally to management and the Board of Trustees. PART XI - RECONCILIATION OF NET ASSETS, LINE 9 OTHER CHANGES IN NET ASSETS OR FUND BALANCES - LOSS ON UNCOLLECTIBLE AMOUNTS OF $2,163,048. CANCER VACCINE ACCELERATION COMPANY 605 THIRD AVENUE 32ND FLOOR NEW YORK NY 10158 273953921 RESEARCH DE CRI LLC 0.50000 false false false false false false false false false false false false false false false false false false false